Last medically reviewed: 2026-04-27 by GLP3 Planner editorial. References inline as available.
Dosing Strategy
What is GLP-1 Microdosing?
Microdosing (or split dosing) means dividing your weekly GLP-1 dose into smaller, more frequent injections. Instead of one large weekly shot, you might take smaller doses every few days or even daily. This approach can significantly reduce side effects while maintaining similar efficacy.
Microdosing guides by medication
Retatrutide
Triple-agonist microdosing protocols. Daily and twice-weekly schedules for retatrutide.
Read guide →
Tirzepatide
Mounjaro/Zepbound split dosing. How to divide your pen doses for better GI tolerability.
Read guide →
Semaglutide
Ozempic/Wegovy microdosing. Splitting strategies for the most widely-used GLP-1 agonist.
Read guide →
Why microdose GLP-1 medications?
Benefits
- Reduced GI side effects: Smaller peaks mean less nausea, the main reason users try split dosing (see retatrutide, tirzepatide, semaglutide side effect guides)
- More stable drug levels: Fewer "peaks and valleys"
- Better tolerability: Easier to stick with treatment
- Flexibility: Adjust doses more precisely
- Faster titration: Some users can increase dose sooner
Considerations
- More injections: Multiple shots per week instead of one
- Tracking complexity: Need to plan doses carefully
- Off-label: Not part of standard protocols
- Reconstitution: May require vials instead of pens
- Limited research: Based on user reports, not trials
Two types of microdosing: what's the difference?
"Microdosing" gets used to describe two distinct strategies. Worth understanding which one you're actually doing before setting up a protocol.
Split dosing (same weekly total)
You take the same weekly dose divided into more frequent injections. A 4mg weekly dose becomes 2mg twice a week. Total drug exposure stays identical.
Goal: Reduce peak blood levels after each injection to ease GI side effects, without changing how much drug your body receives overall.
Sub-threshold microdosing (lower total dose)
You start below the standard starting dose and titrate upward slowly, guided by how your body responds. For semaglutide, this might mean beginning at 0.05mg weekly rather than the standard 0.25mg.
Goal: Let the body adapt incrementally during the adjustment period. More common in clinical settings where a provider adjusts the prescription itself.
Online communities often use both terms interchangeably, which creates real confusion. For compounded peptide users drawing their own doses, split dosing is the more common technique. Sub-threshold microdosing usually involves adjusting the dose prescription itself with a provider's input. The compound-specific tables below cover both approaches.
How microdosing works
GLP-1 medications have long half-lives (5-7 days), meaning the drug stays in your system for extended periods. When you take a large weekly dose, blood levels spike and then gradually decline. This spike is often when side effects are worst.
Weekly vs split dosing example
Standard Weekly Dosing (4mg/week)
Monday: 4mg injection
Peak levels → More nausea
Levels decline through week
Split Dosing (same 4mg/week)
Monday: 2mg injection
Thursday: 2mg injection
Lower peaks → Less nausea
More stable levels
The total weekly dose remains the same; you're just spreading it out. Our GLP-1 Plotter lets you visualize exactly how split dosing affects your drug levels over time.
Common microdosing protocols
Twice weekly (every 3-4 days)
The most common split. Divide your weekly dose in half and inject every 3-4 days.
Example: 4mg/week → 2mg Monday + 2mg Thursday
Every other day (EOD)
For those who need even more stable levels. Divide weekly dose by ~3.5.
Example: 4mg/week → ~1.14mg every other day
Daily microdosing
Maximum stability, minimum peaks. Divide weekly dose by 7.
Example: 4mg/week → ~0.57mg daily
Microdosing protocols by compound
Each compound has a different half-life and standard dosing range, so protocols differ. Here's how microdosing translates for the three main peptides discussed in microdosing protocols.
Semaglutide (Ozempic / Wegovy)
Semaglutide's half-life is around 7 days, the longest of the three compounds. That slow clearance means it takes roughly 5 weeks to reach steady-state after any dose change, which makes microdosing adjustments feel sluggish. Changes take time to register, so patience matters more here than with shorter-acting compounds.
| Parameter | Standard protocol | Sub-threshold microdose | Split dosing |
|---|---|---|---|
| Starting dose | 0.25mg/week | 0.05–0.1mg/week | Weekly dose ÷ 2 |
| Titration pace | Every 4 weeks | Every 6–8 weeks | Match base schedule |
| Common maintenance | 0.5–2.4mg/week | 0.25–0.5mg/week | e.g., 0.5mg twice weekly |
Clinical data shows semaglutide at 1mg/week produces around 16% body weight reduction over 64 weeks in patients who follow a structured protocol, well below the 2.4mg maintenance dose. Many compounded semaglutide users find a maintenance range of 0.5–1mg workable long-term.
Tirzepatide (Mounjaro / Zepbound)
Tirzepatide's half-life is approximately 5 days. Its dual GLP-1 and GIP receptor activity tends to produce stronger appetite suppression than semaglutide at comparable doses, which can make GI side effects sharper when starting too high too fast. Staying at the 2.5mg starting dose for longer than the label's 4-week minimum is one of the most common microdosing strategies for tirzepatide.
| Parameter | Standard protocol | Sub-threshold microdose | Split dosing |
|---|---|---|---|
| Starting dose | 2.5mg/week | 1–2mg/week (compounded) | Weekly dose ÷ 2 |
| Titration pace | Every 4 weeks | Stay at 2.5mg for 8–12 weeks | e.g., 1.25mg twice weekly |
| Common maintenance | 5–15mg/week | 2.5–7.5mg/week | e.g., 2.5mg twice weekly |
A real-world study of over 20,000 adults found tirzepatide at 2.5–7.5mg produced approximately 12% body weight loss at 6 months, meaningful results at doses well below the clinical maximum of 15mg. See the tirzepatide microdosing guide for detailed protocols.
Retatrutide (investigational)
Retatrutide has no FDA-approved dosing schedule. Its triple-agonist activity (GLP-1, GIP, and glucagon receptors) makes it the most potent of the three compounds, and GI side effects at higher doses can be significant. The Phase 2 obesity trial ran a fixed 1mg weekly arm plus 4mg, 8mg and 12mg arms that started at 2mg (or 4mg in some groups) and stepped up every 4 weeks; the 12mg arm went 2mg, 4mg, 8mg, 12mg. A Phase 2 type 2 diabetes trial added a fixed 0.5mg arm. No arm titrated in 0.5mg steps, and no trial tested split or microdosing schedules. Community users often start lower than any trial arm to reduce early side effects. The FDA states retatrutide cannot be used in compounding under US federal law, so compounding pharmacies cannot lawfully supply it. In the US, the routes available today are a clinical trial or Lilly's expanded access program (ClinicalTrials.gov NCT07629401), which a doctor must request, for adults with a BMI of 35 or more whose obesity has not responded to the highest available dose of current weight-loss treatment, who have two or more serious obesity-related complications, and who cannot join a trial. Lilly provides the product at no cost, but the doctor must apply to the FDA as sponsor of a patient-specific investigational new drug (IND) application and obtain IRB approval (per Lilly Medical). Neither route supplies it for self-directed microdosing.
| Parameter | Phase 2 trial arms | Community microdose | Split dosing |
|---|---|---|---|
| Starting dose | 1mg fixed; escalating arms started at 2mg (some at 4mg); T2D trial added a fixed 0.5mg arm | 0.25–0.5mg/week | 0.25mg twice weekly |
| Titration pace | Stepped up every 4 weeks (12mg arm: 2, 4, 8, 12mg); fixed arms did not titrate | +0.25–0.5mg every 6–8 weeks | Match base schedule |
| Common maintenance | 4–12mg/week (trial) | 1–4mg/week (user-guided) | Weekly dose ÷ 2 or ÷ 3 |
⚠️ Retatrutide is investigational with no FDA-approved dosing. The figures above come from Phase 2 trial data and peptide community experience, not clinical recommendations. In the US, lawful access to retatrutide is limited to a clinical trial or Lilly's narrow expanded access program (NCT07629401); most retatrutide Phase 3 trials are no longer enrolling, so check ClinicalTrials.gov for open studies and see retatrutide clinical trials. See the retatrutide microdosing guide for full details.
Use the GLP-1 Plotter to map any of these protocols and see how your drug levels change under different split dosing schedules.
Who should consider microdosing?
Good candidates
- Experiencing significant nausea or vomiting
- Unable to tolerate dose increases
- History of sensitive GI system
- Want more stable appetite suppression
- Comfortable with more frequent injections
May not need it
- Tolerating weekly doses well
- Minimal side effects
- Prefer fewer injections
- Using auto-injector pens (harder to split)
- Already at maintenance dose with no issues
Microdosing tips
Use a calculator
Our dose plotter helps you visualize how different split protocols affect your levels.
Stay consistent
Pick a schedule and stick to it. Irregular dosing can lead to unpredictable side effects.
Track your doses
With multiple injections per week, it's easy to forget. Use the GLP3 Planner app to log each dose.
Same total weekly dose
Microdosing isn't about taking less. It's about spreading the same amount over more injections.
Plan Your Microdosing Protocol
Use our free calculator to compare weekly vs split dosing and see exactly how your drug levels change.
Related resources
Retatrutide Hub
Complete guide to the triple-agonist
Tirzepatide Hub
Mounjaro & Zepbound guide
Understanding Half-Life
Why split dosing works
Reconstitution Guides